DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Conjugate Vaccine Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
Asia-Pacific is the fastest growing market for conjugate vaccines. The conjugate vaccines market in Asia-Pacific is expected to expand at a CAGR of 23.5%, leading to a revenue of USD 66.61 Bn by 2023. By volume, it is anticipated to reach 6,883.55 Million units by 2023, expanding at a CAGR of 21.87%.
A penetration rate of around 95% of DTP conjugate vaccines indicates an excellent coverage in Asia-Pacific countries and very little is left to achieve full penetration for the vaccines. Countries with high populations such as China and India, serve as major target areas for such vaccines, and the introduction of these vaccines would ensure a disease-free society.
Key Growth Factors
The Asia-Pacific has a growing market owing to improvement and advancements in medical science. Awareness about availability of higher number of vaccines as compared to before are major driving factors for the growth of this market.
The primary indicators of the potential for the vaccine market are the geriatric population in Asia and its growth in some countries such as India and China. This has encouraged market participants to increase spending on research and development, and distribution facilities in Asian countries.
The Asia-Pacific Conjugate Vaccine market is expected to grow at a significant rate. But there are issues with regard to health care access and costs. Fragmented health care has a negative impact on the effectiveness of any proposed immunization strategy. Adolescent and adult pertussis is under-recognized by lay and medical communities due to its unique clinical presentation.
- Pfizer Inc.
- Merck & Co.
- Sanofi Pasteur
Other Prominent Players
- CSL Limited
- Bharat Biotech
- Biological E. Limited
- Serum Institute of India
Key Topics Covered
Chapter 1: Executive Summary
Chapter 2: Market Overview
Chapter 3: Asia-Pacific Major Segment Overview - by Disease Indication
Chapter 4: Asia-Pacific Major Segment Overview - by End-User
Chapter 5: China - by Disease Indication
Chapter 6: China - by End-User
Chapter 7: India - by Disease Indication
Chapter 8: India - by End-User
Chapter 9: Japan - by Disease Indication
Chapter 10: Japan - by End-User
Chapter 11: South Korea - by Disease Indication
Chapter 12: South Korea - by End-User
Chapter 13: Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/research/krzwfj/asiapacific?w=4